Bronchiectasis is a heterogeneous condition and may be encountered as a stand-alone pulmonary disease by primary care clinicians and specialists in pulmonary medicine. Bronchiectasis sometimes ...

Bronchiectasis is a condition where the bronchial tubes of your lungs are permanently damaged, widened, and thickened. These damaged air passages allow bacteria and mucus to build up and pool in your ...

Top content from this year's CHEST meeting in Chicago focused on bronchiectasis treatment, particularly the newly FDA-approved brensocatib (Brinspuri; Insmed). Brensocatib improves lung structure and ...

Bronchiectasis may affect anyone of any age, but most commonly the middle-aged segment. Unfortunately, the damage done to the lungs by bronchiectasis is permanent. The bronchi are small tubes in the ...

Glenview, Illinois – On World Bronchiectasis Day (July 1), the American College of Chest Physicians (CHEST) is announcing the launch of Bridging Specialties ®: Timely Diagnosis for NTM Disease and ...

Bronchiectasis is a long-term condition affecting over 200,000 people in the UK. The numbers are rising – over the past ten years the number of people with bronchiectasis has increased by 40 per cent.

Bronchiectasis develops early in the course of cystic fibrosis, being detectable in infants as young as 10 weeks of age, and is persistent and progressive. We sought to determine risk factors for the ...

Miami (October 23, 2025) – The Bronchiectasis and NTM Association announced today that two abstracts using Bronchiectasis and NTM Research Registry data were presented at CHEST 2025, held October ...